A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1484 participants.

Also called NCT01095666

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,484 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01095666
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, India, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01095666. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2017-09-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Intervention (Drug)
Dapagliflozin Placebo
Intervention (Drug)
Pioglitazone
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Astra Zeneca, Bristol-Myers Squibb (class: other)

Record details

Record id
cardio:ct-nct01095666
Content hash
ab259c11c84f41a79e67221167cd0337f35f6d0d4da53064c432284dec6bcd92